相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation
Li Di et al.
AAPS JOURNAL (2021)
Factors Affecting the Pharmacokinetics of Pyrazinamide and Its Metabolites in Patients Coinfected with HIV and Implications for Individualized Dosing
Jesper Sundell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review
Tom G. Jacobs et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization
Natasha Strydom et al.
PLOS MEDICINE (2019)
How long will treatment guidelines for TB continue to overlook variability in drug exposure?
Morris Muliaditan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs
Alper Daskapan et al.
CLINICAL PHARMACOKINETICS (2019)
State-of-the-Art Review of HIV-TB Coinfection in Special Populations
Ethel D. Weld et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV plus Population Is Not Related to Antiretroviral Therapy
M. E. Torok et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Inflammation and pharmacokinetics: potential implications for HIV-infection
Sharon M. Seifert et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Joel Gallant et al.
LANCET (2017)
HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
Neesha Rockwood et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition
Olena Kis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Therapeutic Optimization as Part of the Precision Medicine Paradigm
Alexander A. Vinks
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring
Roger K. Verbeeck et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi
J. J. van Oosterhout et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Role of a GenoType MTBDRplus line probe assay in early detection of multidrug-resistant tuberculosis at a Brazilian reference center
C. S. Feliciano et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2015)
Optimizing the Clinical Pharmacology of Tuberculosis Medications
E. F. Egelund et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Developing and Using Therapeutics for Emerging Infections
Jeannine S. McCune et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution
Oskar Clewe et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2015)
Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives
Laura E. Via et al.
ACS INFECTIOUS DISEASES (2015)
Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update
Abdullah Alsultan et al.
DRUGS (2014)
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial
Beatriz Grinsztejn et al.
LANCET INFECTIOUS DISEASES (2014)
Intestinal drug transporters: An overview
Margarida Estudante et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study
Anne F. Luetkemeyer et al.
CLINICAL INFECTIOUS DISEASES (2013)
Relationship between CES2 genetic variations and rifampicin metabolism
Sang Hoon Song et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes
Jotam G. Pasipanodya et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Pharmacokinetics of Rifampin in Peruvian Tuberculosis Patients with and without Comorbid Diabetes or HIV
Ana Requena-Mendez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications
Emmanuel Chigutsa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals
Dhananjay Pal et al.
LIFE SCIENCES (2011)
HIV Infection-Associated Tuberculosis: The Epidemiology and the Response
Haileyesus Getahun et al.
CLINICAL INFECTIOUS DISEASES (2010)
Effect of treating co-infections on HIV-1 viral load: a systematic review
Kayvon Modjarrad et al.
LANCET INFECTIOUS DISEASES (2010)
Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis from Botswana
Sekai Chideya et al.
CLINICAL INFECTIOUS DISEASES (2009)
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients
H McIlleron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease
P Gurumurthy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy
JB Mehta et al.
CHEST (2001)
分享论文
